OpGen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

OpGen şirketinin toplam hissedar öz sermayesi $3.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $5.5M ve $2.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$1.63m
Eşitlik	US$2.99m
Toplam yükümlülükler	US$2.48m
Toplam varlıklar	US$5.47m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0A8L 'nin kısa vadeli varlıkları ( $3.2M ) kısa vadeli yükümlülüklerini ( $589.8K ) aşıyor.

Uzun Vadeli Yükümlülükler: 0A8L şirketinin kısa vadeli varlıkları ( $3.2M ) uzun vadeli yükümlülüklerini ( $1.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0A8L borçsuzdur.

Borcun Azaltılması: 0A8L şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0A8L şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 0A8L un, serbest nakit akışı her yıl % 1.7 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

OpGen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on Nasdaq

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq

Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024

OpGen Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Due to Not Filing its Quarterly Report on Form 10-Q for the Period Ended March 31, 2024

Recent updates

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on Nasdaq

OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index

OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq

Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024

OpGen Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Due to Not Filing its Quarterly Report on Form 10-Q for the Period Ended March 31, 2024

OpGen, Inc. announced delayed 10-Q filing

OpGen, Inc. Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Nasdaq Capital Market’s Minimum Bid Price Listing Requirement of $1.00 Per Share

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

OpGen, Inc. announced delayed annual 10-K filing

Opgen, Inc. Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$5.92 loss in 3Q 2022)

OpGen, Inc. announced that it expects to receive $1 million in funding

OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023

OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

OpGen, Inc Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Reports Goodwill Impairment Charge for the Third Quarter Ended September 30, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.38 million.

OpGen, Inc. Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

Opgen, Inc. Launches Ares Sequencing Services in the U.S. from Its Rockville, Maryland Laboratory

OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022

OpGen, Inc. to Report Q2, 2022 Results on Aug 11, 2022

OpGen, Inc. Announces Publication of Results of Unyvero Hospitalized Pneumonia (Hpn) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized Covid-19 Patients

OpGen, Inc. Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia Panel in the Lancet Respiratory Medicine

OpGen, Inc. Provides Earnings Guidance for the Year 2022

OpGen, Inc., Annual General Meeting, Jun 09, 2022

OpGen, Inc. Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Provides Revenue Guidance for the Year 2022

OpGen, Inc. Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

OpGen, Inc. Submits Updated 510(k) Summary to FDA For Acuitas AMR Gene Panel for Isolates

First quarter 2021 earnings released: US$0.50 loss per share (vs US$0.53 loss in 1Q 2020)

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin